Advertisement

Denosumab

  • Giuseppe Tridente
Chapter

Abstract

Denosumab (Prolia®, Xgeva®, Amgen) is a human recombinant IgG2k antibody directed to receptor activator of nuclear factor kappa-B ligand (RANKL), and thus inhibiting its interaction with the specific RANK receptor. The blocking interferes with formation, function, and survival of osteoclasts, which are essential for bone resorption.

Keywords

Zoledronic Acid Bone Marrow Stromal Cell Giant Cell Tumor Proportional Reporting Ratio Atypical Fracture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_17_MOESM1_ESM.xls (58 kb)
Supplementary material 1 (XLS 59 kb)

References

  1. 1.
    Denosumab (Prolia®) BLA 125320 FDA Medical Review, 2010Google Scholar
  2. 2.
    Denosumab (Prolia® WC500093526 EMA Summary of product characteristics. Annex I 2012Google Scholar
  3. 3.
    Denosumab (Prolia®) Product Information, Amgen 2013Google Scholar
  4. 4.
    Denosumab (Xgeva®) WC500110381 EMA Summary of product characteristics. Annex I 2012Google Scholar
  5. 5.
    Denosumab (Xgeva®) Product Information, Amgen 2013Google Scholar
  6. 6.
    Stopeck AT, Lipton A, Body J–J et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 35:5132–5139CrossRefGoogle Scholar
  7. 7.
    Fizazi K, Carducci M, Smith M et al (2012) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 377:813–822CrossRefGoogle Scholar
  8. 8.
    Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132CrossRefPubMedGoogle Scholar
  9. 9.
    Horwoll E, Teglbjærg CS, Langdahl BL et al (2012) A randomized, placebo- controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161–3169CrossRefGoogle Scholar
  10. 10.
    Jones H, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696CrossRefPubMedGoogle Scholar
  11. 11.
    Castellano D, Sepulveda JM, Garçia-Escobar I et al (2011) The role of RANK-Ligand inhibition in cancer: the story of Denosumab. Oncologist 16:136–145CrossRefPubMedGoogle Scholar
  12. 12.
    Baron R, Ferrari S, Russell GG (2011) Denosumab and bisphosphonates: different mechanism of action and effects. Bone 48:677–692CrossRefPubMedGoogle Scholar
  13. 13.
    Ferrari-Lacraz S, Ferrari S (2011) Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporosis Int 22:435–446CrossRefGoogle Scholar
  14. 14.
    Denosumab background information for ACRHD, Amgen 13 Aug. 2009Google Scholar
  15. 15.
    Prolia® (denosumab) Product Monograph, Amgen Canada Apr 2011Google Scholar
  16. 16.
    Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials. Eur J Cancer 48:3082–3092CrossRefPubMedGoogle Scholar
  17. 17.
    Lewiecki EM Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. (2011) Drug, Healthcare and Patient Safety 3:79–91Google Scholar
  18. 18.
    Xgeva® (denosumab) Product Monograph, Amgen Canada Aug 2012Google Scholar
  19. 19.
    Smith MR, Saad F, Coleman R et al (2012) Denosumab as bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 379:39–46CrossRefPubMedGoogle Scholar
  20. 20.
    Denosumab (Xgeva®) FDA ODAC Briefing Document BLA 125320/28, Feb 2012Google Scholar
  21. 21.
    Steger GG and Bartsch R (2011) Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 3: 233-243 Google Scholar
  22. 22.
    Lei S, Shiying Y (2012) Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases. A systematic review and meta-analysis. Am J Clin Oncol doi. doi: 10.1097/COC.0b013e31824be20e Google Scholar
  23. 23.
    Knoop KA, Kumar N, Butler BR et al (2009) RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 183:5738–5747CrossRefPubMedGoogle Scholar
  24. 24.
    Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Therap 84:548–558CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations